Cat No.
CEI-0251
Description
VX-770 is an orally bioavailable CFTR potentiator and VX-770 is in clinical development for the treatment of Cystic fibrosis.
CAS No.
873054-44-5
Targets
G551D-CFTR, F508del-CFTR
Chemical Name
N-(2,4-di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide
M.Wt
392.49
Purity
>99%
Solubility
DMSO 79 mg/mL Water
Storage
2 years at -20centigrade Powder
In vitro
VX-770 is an orally bioavailable CFTR potentiator and VX-770 is in clinical development for the treatment of Cystic fibrosis. VX-770 bound directly to the CFTR protein, rather than associated kinases or phosphatases. VX-770 can cause CFTR channel opening through a non-conventional, ATP-independent mechanism. In recombinant cells VX-770 increased CFTR channel open probability (P(o)) in both the F508del processing mutation and the G551D gating mutation. VX-770 also increased Cl(-) secretion in cultured human CF bronchial epithelia (HBE) carrying the G551D gating mutation on one allele and the F508del processing mutation on the other allele by approximately 10-fold, to approximately 50% of that observed in HBE isolated from individuals without CF. VX-770 reduces excessive Na(+) and fluid absorption to prevent dehydration of the apical surface and increased cilia beating in these epithelial cultures.
